FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL										
	OMB Number:	3235-0287									
	Estimated average burden										
-	hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Addres Haley Patrick	2. Issuer Name and Ticker or Trading Symbol EXELIXIS, INC. [EXEL]							ationship of Reporting all applicable) Director	. ,	Person(s) to Issuer				
(Last) (First) (Middle)									X	Officer (give title below)		(specify		
(Last) C/O EXELIXIS,		e of Earliest Transa /2022	action (N	/lonth/	Day/Year)		EVP, Commercial							
1851 HARBOR	If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable						
(Street)					monamont, Date of	. ogc		. (Line)					
ALAMEDA CA 94502											Form filed by One Reporting Person Form filed by More than One Reporting			
										Person				
(City)	(State)	(Zip)												
	Т	able I - No	n-Deriva	ative S	Securities Acc	quired	, Dis	posed of,	or Bei	eficially	Owned			
Date			2. Transact Date (Month/Dat		2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Disposed Of	Acquired (D) (Instr.	(A) or 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
						Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)	
Common Stock				2022		M		10,000	A	\$6.21	279,191(1)	D		
Common Stock				2022		S ⁽²⁾		10,000	D	\$22.43(3)	269,191	D		
Common Stock 04/0				2022		М		10,000	Α	\$6.21	279,191	D		
Common Stock 04/01/						S ⁽²⁾		10,000	D	\$23	269,191	D		
Common Stock											23,539	I	By spouse	
Common Stock											10,648(4)	I	By 401(k)	
		Table II			ecurities Acqualls, warrants,						wned			

1. Title of Derivative Security (Instr. 3) 2. Conversio or Exercis: Price of Derivative Security		3. Transaction Date Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Option (right to buy)	\$6.21	03/31/2022		М			10,000	09/16/2016 ⁽⁵⁾	09/15/2022	Common Stock	10,000	\$0	50,000	D	
Option (right to buy)	\$6.21	04/01/2022		M			10,000	09/16/2016 ⁽⁵⁾	09/15/2022	Common Stock	10,000	\$0	40,000	D	

Explanation of Responses:

- 1. Includes 175,508 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.
- 2. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 1, 2022.
- 3. Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from \$22.32 to \$22.55. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exclixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4
- 4. Represents shares of Exelixis, Inc. common stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of March 30, 2022.
- 5. The option, representing the right to purchase a total of 60,000 shares of Exelixis, Inc. common stock, became fully exercisable on September 16, 2019.

Remarks:

/s/ Christopher J. Senner, Attorney in Fact

04/04/2022

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.